Skip to content
Clinical Trials – home

Unidade Local De Saude Do Alto Minho E.P.E.

Research site

Portugal Estrada De Santa Luzia, 4904-858 Viana Do Castelo, Portugal

  • 10 trials recruiting
  • Crohn's disease · Colitis ulcerative · Metabolic dysfunction-associated steatohepatitis
  • Adults and children

About Specializations

Unidade Local De Saude Do Alto Minho E.P.E. in Viana Do Castelo, Portugal specialises in clinical trials of conditions such as Crohn's disease, Colitis ulcerative, Metabolic dysfunction-associated steatohepatitis, Non-alcoholic steatohepatitis, and other specialisations. This site conducts important research.

Main research areas of the site

Digestive System Diseases

The gastroenterology department at Unidade Local De Saude Do Alto Minho E.P.E. is running clinical investigations that target ulcerative colitis and non‑alcoholic steatohepatitis (NASH), with the goal of evaluating new therapies that could enhance intestinal healing and improve liver health.

  • Assessment of obefazimod for endoscopic improvement and symptom remission in ulcerative colitis
  • Evaluation of semaglutide for liver histology improvement and reduced clinical events in NASH patients

These trials aim to expand treatment options for digestive system disorders and support better outcomes for patients in the Viana Do Castelo region.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Estrada De Santa Luzia4904-858 Viana Do CasteloPortugal
Recruiting now
10 trials
Conditions studied
18

More sites in Viana Do CasteloPortugal

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

23 clinical trials

Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Study on the Effects of Filgotinib for Children and Teenagers with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Muscle spasticity

Not recruiting

Study on the Safety and Effectiveness of IPN10200 for Treating Upper Limb Spasticity in Adults After Stroke or Brain Injury

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.